title: [Renin-angiotensin system in diabetic nephropathy].
abstract: The importance of the renin angiotensin system (RAS) in the development and progression of the diabetic nephropathy is confirmed with the recent demonstration that the development of nephropathy in the diabetic patients can be avoided by blockers of the RAS. For that reason, the promotion of preventive programs for the detection of microalbuminuria, from the early phases of the diabetes is needed. Control of blood pressure, of glucose and lipids are needed. If microalbuminuria is present, the administration of a blocker of RAS, even in the presence of normal blood pressure can prevent the progression to diabetic nephropathy. The main objective to prevent the development and progression of nephropathy in the diabetic patients, as well as the cardiovascular risk, is a strict control of the PA.
authors.affiliation: Jefe del Servicio de Nefrología, Hospital General Universitario Gregorio Marañón, Madrid. jluno.hgugm@salud.madrid.org
authors.forename: J
authors.initials: J
authors.lastname: Luño
mesh_terms: D000419:Albuminuria / Q000175:diagnosis; D047228:Angiotensin II Type 1 Receptor Blockers / Q000008:administration & dosage / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use; D000818:Animals; D000959:Antihypertensive Agents / Q000008:administration & dosage / Q000627:therapeutic use; D001562:Benzimidazoles / Q000008:administration & dosage / Q000627:therapeutic use; D001565:Benzoates / Q000008:administration & dosage / Q000627:therapeutic use; D001786:Blood Glucose / Q000032:analysis; D003924:Diabetes Mellitus, Type 2 / Q000150:complications; D003928:Diabetic Nephropathies / Q000097:blood / Q000503:physiopathology* / Q000517:prevention & control*; D018450:Disease Progression; D004359:Drug Therapy, Combination; D006706:Homeostasis; D006801:Humans; D017706:Lisinopril / Q000008:administration & dosage / Q000627:therapeutic use; D019808:Losartan / Q000008:administration & dosage / Q000627:therapeutic use; D015201:Meta-Analysis as Topic; D016032:Randomized Controlled Trials as Topic; D012084:Renin-Angiotensin System / Q000187:drug effects* / Q000502:physiology; D012307:Risk Factors; D000077333:Telmisartan
chemical_list: D047228:Angiotensin II Type 1 Receptor Blockers; D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D001562:Benzimidazoles; D001565:Benzoates; D001786:Blood Glucose; D017706:Lisinopril; D019808:Losartan; D000077333:Telmisartan